1. Home
  2. Analysis
  3. Fluocinonide
  4. Peginterferon

Fluocinonide and Peginterferon drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fluocinonide (fluocinonide) and Peginterferon (peginterferon alfa-2a; ribavirin). Common drug interactions include dehydration among males.

The phase IV clinical study analyzes what interactions people have when they take Fluocinonide and Peginterferon. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Fluocinonide?

Fluocinonide has active ingredients of fluocinonide. It is often used in eczema. eHealthMe is studying from 6,385 Fluocinonide users. Check the latest studies of Fluocinonide.

What is Peginterferon?

Peginterferon has active ingredients of peginterferon alfa-2a; ribavirin. It is often used in hepatitis c. eHealthMe is studying from 13,778 Peginterferon users. Check the latest studies of Peginterferon.

On Jul, 12, 2026

11 people who take Fluocinonide and Peginterferon together, and have interactions are studied.

Fluocinonide and Peginterferon drug interactions.

What are the common drug interactions of Fluocinonide and Peginterferon, by gender? *:

female:

n/a

male:

  1. Dehydration (dryness resulting from the removal of water)
  2. Migraine (headache)
  3. Drug eruption (adverse drug reaction of the skin)
  4. Proctalgia (pain in the rectum)
  5. Traumatic haematoma (a blood clot in body due to trauma)
  6. Haemoglobin decreased
  7. Drug intolerance (drug sensitivity)
  8. Nausea (feeling of having an urge to vomit)
  9. Rash
  10. White blood cell count increased

What are the common drug interactions of Fluocinonide and Peginterferon, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Traumatic haematoma (a blood clot in body due to trauma)

30-39:

n/a

40-49:

n/a

50-59:

  1. Dehydration (dryness resulting from the removal of water)
  2. Migraine (headache)
  3. Haemoglobin decreased
  4. Nausea (feeling of having an urge to vomit)
  5. Rash

60+:

  1. Drug eruption (adverse drug reaction of the skin)
  2. Proctalgia (pain in the rectum)
  3. Drug intolerance (drug sensitivity)
  4. White blood cell count increased

What are the existing conditions these people have? *

  1. Otitis Media (inflammation of the middle ear): 5 people, 45.45%
  2. Insomnia (sleeplessness): 5 people, 45.45%
  3. Headache (pain in head): 5 people, 45.45%
  4. Depression: 5 people, 45.45%
  5. Wound Infection: 3 people, 27.27%
  6. Muscle Aches (muscle pain): 2 people, 18.18%
  7. Stomatitis (inflammation of mucous membrane of mouth): 1 person, 9.09%
  8. Seasonal Allergy (allergic condition due to certain season): 1 person, 9.09%
  9. Rickets (softening of bones): 1 person, 9.09%
  10. Rashes (redness): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Fluocinonide and Peginterferon?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Fluocinonide and Peginterferon:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fluocinonide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Peginterferon:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Fluocinonide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Peginterferon and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on fluocinonide and peginterferon alfa-2a; ribavirin (the active ingredients of Fluocinonide and Peginterferon, respectively), and Fluocinonide and Peginterferon (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.